Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

被引:65
作者
Zhou, J
Wang, W
Zhong, Q
Hou, W
Yang, ZQ [1 ]
Xiao, SY
Zhu, RQ
Tang, ZJ
Wang, Y
Xian, QY
Tang, HB
Wen, L
机构
[1] Wuhan Univ, Inst Virol, Minist Educ, Key Lab Virol, Wuhan 430071, Peoples R China
[2] Wuhan Univ, Sch Med, Dept Pathol, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Sch Med, Expt Anim Ctr, Wuhan 430071, Peoples R China
[4] Univ Texas, Dept Pathol, Med Branch, Galveston, TX 77555 USA
[5] Univ Texas, Dept Internal Med, Med Branch, Galveston, TX 77555 USA
关键词
SARS-CoV; inactivated vaccine; rhesus monkeys;
D O I
10.1016/j.vaccine.2004.11.075
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An inactivated vaccine for severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was evaluated in rhesus monkeys. The monkeys were inoculated intramuscularly (i.m.) with 0.5, 5, 50, or 5000 mu g of vaccine, or PBS as control, and boosted on day 7. After 3 weeks, they were challenged with the NS-1 strain of SARS-CoV The humoral and mucosal immune responses, clinical signs, chemical indices and viremia were monitored following the immunization and challenge. The control animals who received PBS developed atypical SAR-CoV infection after viral challenge, according to clinical, virological and pathological findings. No systematic side effects were observed in vaccinated animals post-immunization, even in at the high dose of 5000 mu g. The 50 mu g dosage of vaccine elicited SARS-CoV specific immune responses against viral infection as compared to the partial immunity elicited by 0.5 and 5 mu g doses. The results show that this inactivated vaccine can induce effective concomitant humoral and mucosal immunity against SARS-CoV infection, is safe in monkeys, and the vaccine maybe a good candidate for clinical trials. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3202 / 3209
页数:8
相关论文
共 21 条
[1]  
ABRIGNANI S, 2003, DEV SARS VIRUS VACCI
[2]   Custom-made vaccines at speed [J].
Bradbury, J .
DRUG DISCOVERY TODAY, 2003, 8 (12) :518-519
[3]   SERUM AND NASAL WASH ANTIBODIES ASSOCIATED WITH RESISTANCE TO EXPERIMENTAL CHALLENGE WITH INFLUENZA-A WILD-TYPE VIRUS [J].
CLEMENTS, ML ;
BETTS, RF ;
TIERNEY, EL ;
MURPHY, BR .
JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 24 (01) :157-160
[4]   The clinical pathology of severe acute respiratory syndrome (SARS): a report from China [J].
Ding, YQ ;
Wang, HJ ;
Shen, H ;
Li, ZG ;
Geng, J ;
Han, HX ;
Cai, JJ ;
Li, X ;
Kang, W ;
Weng, DS ;
Lu, YD ;
Wu, DH ;
He, L ;
Yao, KT .
JOURNAL OF PATHOLOGY, 2003, 200 (03) :282-289
[5]   Aetiology -: Koch's postulates fulfilled for SARS virus [J].
Fouchier, RAM ;
Kuiken, T ;
Schutten, M ;
van Amerongen, G ;
van Doornum, J ;
van den Hoogen, BG ;
Peiris, M ;
Lim, W ;
Stöhr, K ;
Osterhaus, ADME .
NATURE, 2003, 423 (6937) :240-240
[6]   Effects of a SARS-associated coronavirus vaccine in monkeys [J].
Gao, WT ;
Tamin, A ;
Soloff, A ;
D'Aiuto, L ;
Nwanegbo, E ;
Robbins, PD ;
Bellini, WJ ;
Barratt-Boyes, S ;
Gambotto, A .
LANCET, 2003, 362 (9399) :1895-1896
[7]   Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus [J].
Hohdatsu, T ;
Yamada, M ;
Tominaga, R ;
Makino, K ;
Kida, K ;
Koyama, H .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 1998, 60 (01) :49-55
[8]  
KATHRYN VH, 2003, CLIN INVESTIGATOR, V111, P1605
[9]   A novel coronavirus associated with severe acute respiratory syndrome [J].
Ksiazek, TG ;
Erdman, D ;
Goldsmith, CS ;
Zaki, SR ;
Peret, T ;
Emery, S ;
Tong, SX ;
Urbani, C ;
Comer, JA ;
Lim, W ;
Rollin, PE ;
Dowell, SF ;
Ling, AE ;
Humphrey, CD ;
Shieh, WJ ;
Guarner, J ;
Paddock, CD ;
Rota, P ;
Fields, B ;
DeRisi, J ;
Yang, JY ;
Cox, N ;
Hughes, JM ;
LeDuc, JW ;
Bellini, WJ ;
Anderson, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1953-1966
[10]  
Montagnon B J, 1989, Dev Biol Stand, V70, P27